ArticleScientific reports2025
Enlargement of microvascular dropout toward the disc-fovea axis indicates new central visual field defect in glaucoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We aimed to evaluate the relationship between the increase in choroidal microvascular dropout (MvD) toward the disc-fovea axis and the development of central visual field defect (CVFD) in patients with glaucoma. We retrospectively reviewed the longitudinal medical records of patients who underwent at least two optical coherence tomography angiographies (OCTA) with significant macular retinal ganglion cell (RGC) damage at baseline. Patients were divided into three groups: Group 1, no CVFD; Group 2, new CVFD during the follow-up period; and Group 3, CVFD at baseline. The angular extent of MvD and the change were investigated. We had 35 eyes in Group 1, 25 in Group 2, and 43 in Group 3 with OCTA over an average of 3.1 ± 1.3 years. At baseline, MvD was significantly more frequent and larger in Group 3 compared to Groups 1 and 2; there was no difference between Groups 1 and 2, aligning with the absence of baseline CVFD. The mean final MvD extent was significantly smaller in Group 1 (9.9°) than Groups 2 and 3 (43.6 and 44.8°, P < 0.001), also aligning with the presence of final CVFD. Quantitatively, Group 2 with developing CVFD exhibited significantly greater mean increase in MvD (17.8°) than Groups 1 and 3 (0.9 and 6.0°, P < 0.001). In contrast, the changes in OCT-based thicknesses did not differ among the three groups in the period. In conclusion, in patients with glaucoma who had significant RGC damage in the macular area, longitudinal increase in MvD coincided with development of new CVFD, both in terms of the presence and in terms of angular extent, in a three-year follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.